A board-certified dermatologist with more than 30 years of professional experience, David Amato, DO, FAAD, has a great depth of knowledge of a vast array of dermatologic indications from both a clinical and a research vantage point. His multifaceted career combines both clinical practice and drug development experience, putting him in a unique position to understand the needs and perspectives of both patients and biopharmaceutical companies.
As a Senior Medical Director with IQVIA Biotech, Dr. Amato provides strategic, medical and scientific guidance to clinical trial sponsors regarding dermatology drug development programs from preclinical study protocol design through regulatory approval and commercialization of treatments. Working alongside a team of experts in dermatology and clinical trials, Dr. Amato helps trial sponsors understand and navigate through the key clinical, safety and efficacy variables that must be considered when developing a treatment, while also ensuring patient health and safety.
Dr. Amato’s commitment to dermatology stems from his interest in understanding the complexities of skin conditions and his awareness of the psychosocial impact that dermatologic anomalies have on patients. With more than 20 years of clinical practice, Dr. Amato provided personalized care for patients living with psoriasis, atopic dermatitis, autoimmune and inflammatory skin conditions and hair and nail disorders among many others and was renowned for his expertise in aesthetic and surgical components of dermatology. He incorporated innovative therapeutic advancements such as immunodermatology and the use of biologics, and patient-centric solutions like telehealth into his dermatology practice decades ago. Dr. Amato’s commitment to providing top line care integrating cutting edge therapies with patient care was reflected by his having office hours within his practice for IV administration of newly approved biologic agents for dermatologic conditions for his patients. His determination to help patients living with devastating skin diseases is what continues to fuel his interest in research.
Prior to joining IQVIA Biotech, Dr. Amato’s industry experience includes his service as a field based medical director for Centocor Ortho Biotech, now Janssen Biotech, leading medical monitoring responsibilities for late phase biologic trials for psoriasis treatments. Dr. Amato then built on his breadth of experience to become senior medical advisor for Eli Lilly and Company. There he worked with both global and U.S. lead teams on the highly successful launch of ixekizumab, a breakthrough anti IL-17 biologic for psoriasis. From developing and overseeing large Phase 3b and 4 trials to collaborations with medical affairs team members and regulatory experts, Dr. Amato was an integral leader in development and commercialization of plans and processes.
A lifelong learner, Dr. Amato is an active member of the American Academy of Dermatology and American Society for Dermatologic Surgery. He is also contributing author to more than 20 articles and abstracts in peer-reviewed journals.
From completing his fellowship in dermatology at the University of Pittsburgh to his role now with IQVIA Biotech, Dr. Amato’s commitment to providing stellar medical guidance from his role of clinician to that of researcher is unwavering. Dr. Amato leverages his firsthand experience with patients and deep therapeutic expertise to provide dermatologic guidance to trial sponsors as they strive to meet their research goals, while keeping patient safety at the heart of it all.
Having a team with expertise in your therapeutic area is crucial to the success of your clinical development program. Contact us to learn how our dedicated dermatology team can support your next study.